Atossa Therapeutics (ATOS)’ (Z)-endoxifen was granted FDA orphan designation as a treatment of Duchenne muscular dystrophy, according to a post to the agency’s website.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATOS:
- Atossa Therapeutics outlines strategy for lead (Z)-Endoxifen program
- Atossa Wins FDA Clearance to Advance (Z)-Endoxifen Trial
- Atossa Therapeutics receives “Study May Proceed” letter for breast cancer study
- Atossa Therapeutics: Buy Rating on Promising DMD Advancements and Strategic Growth Potential
- Promising Clinical Trial Results of Z-endoxifen Support Buy Rating for Atossa Therapeutics